Autoimmune lymphoproliferative syndrome: A human disorder of abnormal lymphocyte survival

Pediatric Clinics of North America

Volumn 47, Issue 6, 2000, Pages 1291-1310

  Bleesing, Jack J H ^a   Straus, Stephen E ^b   Fleisher, Thomas A ^a,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL FEATURE; DISEASE CLASSIFICATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; PROGNOSIS; REVIEW;

EID: 0034536284     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-3955(05)70272-8     Document Type: Article

References (66)

1. Identification of new mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia
2. Dyserythropoiesis associated with a Fas-deficient condition in childhood
3. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia
4. Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation
5. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunological analysis
6. Management of chronic immune thrombocytopenic purpura in children and adults
7. -) T cells with an α/β T cell receptor: Non-MHC-restricted cytolytic activity and lymphokine production
8. Chronic lymphadenopathy simulating malignant lymphoma
9. Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease
10. Chronic lymphoproliferative disorders: An integrated point of view for the differential diagnosis
11. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions
12. Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmune/lymphoproliferation
13. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity
14. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome
15. Characteristic T helper 2 T cell cytokine abnormalities in autoimmune lymphoproliferative syndrome: A syndrome marked by defective apoptosis and humoral autoimmunity
16. + double-negative T cells as the predominant population in enlarged lymph nodes
17. Somatic Fas mutations in non-Hodgkin's lymphoma: Association with extranodal disease and autoimmunity
18. Increased spontaneous apoptosis in double negative T cells of humans with a fas/apo-1 mutation
19. Faces and phases of human CD8 T-cell development
20. -) alpha beta T-cell receptor positive cells from an immunodeficient patient
21. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis
22. Autoimmune lymphoproliferative syndrome with defective Fas: Genotype influences penetrance
23. Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder
24. Chronische pseudomaligne immunproliferation (Canale-Smith-Syndrom)
25. Lymphadenopathy in children
26. Immunodeficiency-associated lymphoproliferative disorders
27. Mutations in the Fas antigen in patients with multiple myeloma
28. + TCR-β(low) cells
29. Clinical, immunological, and pathological consequences of Fas-deficient conditions
30. Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scar
31. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer
32. Alterations of Fas (Apo-1/CD95) gene in transitional cell carcinomas of urinary bladder
33. Mature lymphocyte apoptosis: Immune regulation in a dynamic and unpredictable antigenic environment
34. Pathological findings in human autoimmune lymphoproliferative syndrome
35. Fas gene mutation in the progression of adult T cell leukemia
36. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia
37. Chronic lymphoproliferative disorders
38. ALPS (autoimmune lymphoproliferative syndrome) associated with a mutation in Fas ligand
39. A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice
40. Fas/APO1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis
41. Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma and Hodgkin's disease
42. Interleukin-2 reverses the defect in activation-induced apoptosis in T cells from autoimmune lpr mice
43. Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations
44. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity
45. Clinical experience with anti-D in the treatment of idiopathic thrombocytopenic purpura
46. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma
47. T cell receptor α/β expressing double negative and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis
48. The role of Fas and related death receptors in autoimmune and other disease states
49. Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation
50. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease
51. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal apoptosis
52. An inherited disorder of lymphocyte apoptosis: The autoimmune lymphoproliferative syndrome
53. Reversible monoclonal lymphadenopathy in autoimmune lymphoproliferative syndrome with functional FAS (CD95/APO-1) deficiency
54. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand
55. CD5 B cells in autoimmunity
56. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemic cells
57. Murine models of systemic lupus erythematosus
58. The molecular basis for apoptotic defects in patients with CD95 (Fas/APO-1) mutations
59. The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations
60. Revision of the diagnosis of T-zone lymphoma in the father of a patient with autoimmune lymphoproliferative syndrome type II
61. The use of the anti-malaria drug Fansidar (pyrimethamine and sulphadoxine) in the treatment of a patient with autoimmune lymphoproliferative syndrome and Fas deficiency
62. Does 'death receptor' signaling play a role in tumorigenesis and cancer therapy?
63. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II
64. Lymphoproliferative disorder in mice explained by defects in Fas antigen that mediates apoptosis
65. Novel T-lymphocyte population in combined immunodeficiency with features of graft-versus-host disease
66. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease